Publikasi

General Leonard Wood Community Hospital Opens at Fort L...

After six years of construction, Fort Leonard Wood marked the opening of the new...

Flat Handrail

Wallprotex’s wX7 Flat Handrail is a commercial vinyl handrail designed for high-...

Alexandria Supino on Leading Gresham Smith’s Charlotte ...

Alexandria Supino, AIA, NCARB, EDAC, recently joined Gresham Smith’s Charlotte, ...

Powering the Future of Cognitive Care at USC’s New Brai...

Located on its Health Sciences Campus in Columbia, S.C., the University of South...

DesignGroup Welcomes Christian Kyle Jordan Perry as Sen...

Christian Kyle Jordan Perry recently joined DesignGroup as Senior Lab Planner. ...

Drug Target for Fragile X Syndrome Identified Through P...

Researchers identified the synaptic protein EPAC2 as a potential therapeutic tar...

Organ-on-Chip Method Designed to Zero In on Connection ...

A University of Bath, University of Oxford, and Johns Hopkins team is using orga...

Multiple Sclerosis Myelin Loss Revealed by Transcriptom...

A new study compares two prevailing models, cuprizone (CPZ) and lysophosphatidyl...

An SPF Reset Guide for Summer Sun Protection  

Do’s and Don’ts for Healthier Skin All Summer Long   After months of covering up...

Time Management in Med School: Balancing Class, Boards,...

Medical school is not just more school, it’s essentially a full-time job as you ...

BIO supports and seeks refinements to FDA’s Plausible M...

Advances in individualized therapies targeting specific genetic conditions offer...

Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF

Jascayd is said to be the first phosphodiesterase 4B (PDE4B) inhibitor with anti...

Kotak Alts invests INR 200 Million in Cellogen Therapeu...

Kotak Alternate Asset Managers Limited (Kotak Alts), through its Kotak Life Sci...

Annora Pharma expands collaboration with AI-native trac...

Annora Pharma, the formulations subsidiary of Hetero Group and a leading Indian...

Transforming smiles with Venus Pearl composite

Haroon Latiff shares his journey into cosmetic dentistry and why Venus Pearl rem...

FDA approves Enhertu for two HER2-positive early breast...

Data from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials support the...